Engitix

Engitix

Rethinking Drug Discovery for Fibrosis and Cancer - To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD334—501m (Dealroom.co estimates Jan 2022.)
Company register number 10290441
London England (HQ)
Authorizing premium user...